Endoscopic eradication therapy for mucosal neoplasia in Barrett's esophagus

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: Endoscopic eradication therapy is frequently used to treat dysplasia and early cancers in Barrett's esophagus. This review addresses some of the recent developments in the field of endoscopic eradication therapy for Barrett's esophagus. RECENT FINDINGS: Data on the effectiveness of Barrett's esophagus ablation programs have been published recently, with excellent results for dysplasia eradication. Studies describing long-term results have shed light on the durability of endoscopic ablation, with recurrence of Barrett's esophagus and neoplasia seen in some cases, particularly at the gastroesophageal junction. Risk factors for failed ablation include longer Barrett's esophagus segments and persistent gastroesophageal reflux. New developments include studies combining radiofrequency ablation (RFA) and endoscopic mucosal resection into a single endoscopic session, endoscopic submucosal dissection for Barrett's esophagus neoplasia, and a simplified RFA algorithm. New data on the cost-effectiveness of RFA have also been published, suggesting that RFA is cost-effective for both high-grade and low-grade dysplasia, but not for nondysplastic Barrett's esophagus. A systematic review has shown that lymph node metastases are rare (∼2%) with intramucosal adenocarcinoma, supporting the use of endoscopic eradication for that lesion. SUMMARY: Research and clinical experience with the endoscopic therapies for Barrett's esophagus continue to grow. Proper patient selection and technique are critical for ensuring a good outcome. Endoscopic surveillance after any of the ablative therapies still appears to be necessary.

Original languageEnglish (US)
Pages (from-to)446-453
Number of pages8
JournalCurrent Opinion in Gastroenterology
Volume29
Issue number4
DOIs
StatePublished - Jul 2013

Fingerprint

Barrett Esophagus
Neoplasms
Therapeutics
Esophagogastric Junction
Gastroesophageal Reflux
Patient Selection
Cost-Benefit Analysis
Adenocarcinoma
Lymph Nodes
Neoplasm Metastasis
Costs and Cost Analysis
Recurrence
Research

Keywords

  • Barrett's esophagus
  • cryotherapy
  • dysplasia
  • endoscopic mucosal resection
  • radiofrequency ablation

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Endoscopic eradication therapy for mucosal neoplasia in Barrett's esophagus. / Dunbar, Kerry B.

In: Current Opinion in Gastroenterology, Vol. 29, No. 4, 07.2013, p. 446-453.

Research output: Contribution to journalArticle

@article{c61025f54fbc4e3f859e2f3e759a98a0,
title = "Endoscopic eradication therapy for mucosal neoplasia in Barrett's esophagus",
abstract = "PURPOSE OF REVIEW: Endoscopic eradication therapy is frequently used to treat dysplasia and early cancers in Barrett's esophagus. This review addresses some of the recent developments in the field of endoscopic eradication therapy for Barrett's esophagus. RECENT FINDINGS: Data on the effectiveness of Barrett's esophagus ablation programs have been published recently, with excellent results for dysplasia eradication. Studies describing long-term results have shed light on the durability of endoscopic ablation, with recurrence of Barrett's esophagus and neoplasia seen in some cases, particularly at the gastroesophageal junction. Risk factors for failed ablation include longer Barrett's esophagus segments and persistent gastroesophageal reflux. New developments include studies combining radiofrequency ablation (RFA) and endoscopic mucosal resection into a single endoscopic session, endoscopic submucosal dissection for Barrett's esophagus neoplasia, and a simplified RFA algorithm. New data on the cost-effectiveness of RFA have also been published, suggesting that RFA is cost-effective for both high-grade and low-grade dysplasia, but not for nondysplastic Barrett's esophagus. A systematic review has shown that lymph node metastases are rare (∼2{\%}) with intramucosal adenocarcinoma, supporting the use of endoscopic eradication for that lesion. SUMMARY: Research and clinical experience with the endoscopic therapies for Barrett's esophagus continue to grow. Proper patient selection and technique are critical for ensuring a good outcome. Endoscopic surveillance after any of the ablative therapies still appears to be necessary.",
keywords = "Barrett's esophagus, cryotherapy, dysplasia, endoscopic mucosal resection, radiofrequency ablation",
author = "Dunbar, {Kerry B.}",
year = "2013",
month = "7",
doi = "10.1097/MOG.0b013e3283622848",
language = "English (US)",
volume = "29",
pages = "446--453",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Endoscopic eradication therapy for mucosal neoplasia in Barrett's esophagus

AU - Dunbar, Kerry B.

PY - 2013/7

Y1 - 2013/7

N2 - PURPOSE OF REVIEW: Endoscopic eradication therapy is frequently used to treat dysplasia and early cancers in Barrett's esophagus. This review addresses some of the recent developments in the field of endoscopic eradication therapy for Barrett's esophagus. RECENT FINDINGS: Data on the effectiveness of Barrett's esophagus ablation programs have been published recently, with excellent results for dysplasia eradication. Studies describing long-term results have shed light on the durability of endoscopic ablation, with recurrence of Barrett's esophagus and neoplasia seen in some cases, particularly at the gastroesophageal junction. Risk factors for failed ablation include longer Barrett's esophagus segments and persistent gastroesophageal reflux. New developments include studies combining radiofrequency ablation (RFA) and endoscopic mucosal resection into a single endoscopic session, endoscopic submucosal dissection for Barrett's esophagus neoplasia, and a simplified RFA algorithm. New data on the cost-effectiveness of RFA have also been published, suggesting that RFA is cost-effective for both high-grade and low-grade dysplasia, but not for nondysplastic Barrett's esophagus. A systematic review has shown that lymph node metastases are rare (∼2%) with intramucosal adenocarcinoma, supporting the use of endoscopic eradication for that lesion. SUMMARY: Research and clinical experience with the endoscopic therapies for Barrett's esophagus continue to grow. Proper patient selection and technique are critical for ensuring a good outcome. Endoscopic surveillance after any of the ablative therapies still appears to be necessary.

AB - PURPOSE OF REVIEW: Endoscopic eradication therapy is frequently used to treat dysplasia and early cancers in Barrett's esophagus. This review addresses some of the recent developments in the field of endoscopic eradication therapy for Barrett's esophagus. RECENT FINDINGS: Data on the effectiveness of Barrett's esophagus ablation programs have been published recently, with excellent results for dysplasia eradication. Studies describing long-term results have shed light on the durability of endoscopic ablation, with recurrence of Barrett's esophagus and neoplasia seen in some cases, particularly at the gastroesophageal junction. Risk factors for failed ablation include longer Barrett's esophagus segments and persistent gastroesophageal reflux. New developments include studies combining radiofrequency ablation (RFA) and endoscopic mucosal resection into a single endoscopic session, endoscopic submucosal dissection for Barrett's esophagus neoplasia, and a simplified RFA algorithm. New data on the cost-effectiveness of RFA have also been published, suggesting that RFA is cost-effective for both high-grade and low-grade dysplasia, but not for nondysplastic Barrett's esophagus. A systematic review has shown that lymph node metastases are rare (∼2%) with intramucosal adenocarcinoma, supporting the use of endoscopic eradication for that lesion. SUMMARY: Research and clinical experience with the endoscopic therapies for Barrett's esophagus continue to grow. Proper patient selection and technique are critical for ensuring a good outcome. Endoscopic surveillance after any of the ablative therapies still appears to be necessary.

KW - Barrett's esophagus

KW - cryotherapy

KW - dysplasia

KW - endoscopic mucosal resection

KW - radiofrequency ablation

UR - http://www.scopus.com/inward/record.url?scp=84879940239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879940239&partnerID=8YFLogxK

U2 - 10.1097/MOG.0b013e3283622848

DO - 10.1097/MOG.0b013e3283622848

M3 - Article

C2 - 23703368

AN - SCOPUS:84879940239

VL - 29

SP - 446

EP - 453

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 4

ER -